The QMN Weekly Bulletin
Aug. 29, 2011
| Vol.
3 No.
34
The FDA has warned Polish pharmaceutical manufacturer Jelfa SA, citing “worrisome” cGMP deficiencies, including a number of repeat violations.
The FDA has warned Peace Medical for several GMP issues, including failure to provide design control procedures, and for marketing its devices without approval or agency consent.
Johnson & Johnson (J&J) subsidiary McNeil Consumer Healthcare is again recalling Tylenol products, this time for higher-than-expected levels of a compound.
Pharmaceutics International announced it has successfully completed the first-ever US-based joint European Medicines Agency and Food and Drug Administration inspection.
Teva Pharmaceutical is facing a second trial over hepatitis cases linked to propofol.
Ajanta Pharma said it has received approval from the UK health regulator for its formulation manufacturing facility in Aurangabad.
Astellas Pharma has closed a deal to relocate its base of UK operations to a new, larger site in Surrey.
A total of 250 jobs are to be created in the expansion of a pharmaceutical plant in Carrigtwohill, County Cork.
U.S. drug firm Amgen is to create 100 jobs at its factory in Dublin.
|
Register Now
Archives
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews
All rights reserved. Do not duplicate or redistribute in any form.